JNJ

190.21

-0.2%↓

ABT

127.08

+0.24%↑

MDT

93.77

0%↓

VEEV

295.04

+0.62%↑

147.13

-0.73%↓

JNJ

190.21

-0.2%↓

ABT

127.08

+0.24%↑

MDT

93.77

0%↓

VEEV

295.04

+0.62%↑

147.13

-0.73%↓

JNJ

190.21

-0.2%↓

ABT

127.08

+0.24%↑

MDT

93.77

0%↓

VEEV

295.04

+0.62%↑

147.13

-0.73%↓

JNJ

190.21

-0.2%↓

ABT

127.08

+0.24%↑

MDT

93.77

0%↓

VEEV

295.04

+0.62%↑

147.13

-0.73%↓

JNJ

190.21

-0.2%↓

ABT

127.08

+0.24%↑

MDT

93.77

0%↓

VEEV

295.04

+0.62%↑

147.13

-0.73%↓

Strona główna・Stock List・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Open

SectorHealthcare

26.18 -0.68

Buy Sell

Overview

Share price change

24h

Current

Min

25.75

Max

26.46

Key metrics
By Trading Economics
Income	7.7M -41M
Sales	3.5M 110M
Profit margin	-37.032
Employees	1,869
EBITDA	1.4M -55M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+111.36% upside

Dividends
By Dow Jones
Next Earnings	6 lis 2025

Market Stats
By TradingEconomics
Market Cap	-1B 3.2B
Previous open	26.86
Previous close	26.18

News Sentiment

By Acuity

100%

357 / 373 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

28.13 / 31.12 Support & Resistance

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 paź 2025, 23:52 UTC

Market Talk

Global Equities Roundup: Market Talk

26 paź 2025, 23:52 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

26 paź 2025, 23:46 UTC

Market Talk

Oil Rises Amid Ongoing Supply Concerns -- Market Talk

26 paź 2025, 23:41 UTC

Market Talk

Gold Falls; U.S.-China Trade Deal Optimism Overcomes Signs of Cooler U.S. Inflation -- Market Talk

26 paź 2025, 23:34 UTC

Earnings

Sinopharm Group 9-Mos Oper Pft CNY10.87B Vs. Pft CNY10.84B >1099.HK

26 paź 2025, 23:32 UTC

Earnings

Sinopharm Group 9-Mos Net CNY5.31B Vs. Net CNY5.28B >1099.HK

26 paź 2025, 23:30 UTC

Earnings

Sinopharm Group 9-Mos Rev CNY431.48B Vs. CNY442.42B >1099.HK

26 paź 2025, 22:29 UTC

Earnings

WuXi AppTec 3Q Rev CNY12.06B ; up 15.3% on Year>603259.SH

26 paź 2025, 22:29 UTC

Earnings

WuXi AppTec: Higher Contributions From Contract Research Development and Manufacturing Organization Unit Supported Results>603259.SH

26 paź 2025, 22:29 UTC

Earnings

WuXi AppTec: Results Also Boosted From Divestment Gains >603259.SH

26 paź 2025, 22:29 UTC

Earnings

WuXi AppTec 3Q Net CNY5.13B ; up 82.9% on Year>603259.SH

26 paź 2025, 22:16 UTC

Earnings

Stock Futures Rise Ahead of Mag 7 Earnings, Fed Decision -- Barrons.com

26 paź 2025, 21:33 UTC

Acquisitions, Mergers, Takeovers

Novartis Agrees to Acquire Avidity Biosciences for $12 Billion -- WSJ

26 paź 2025, 19:29 UTC

Acquisitions, Mergers, Takeovers

Novartis Deal Values Avidity Biosciences At $12 Billion -- Barrons.com

26 paź 2025, 06:39 UTC

Earnings

CITIC Securities 3Q Rev CNY22.78B Vs. CNY15.96B >6030.HK

26 paź 2025, 06:39 UTC

Earnings

CITIC Securities: Higher Income From Brokerage, Investment Banking Supported Results>6030.HK

26 paź 2025, 06:39 UTC

Earnings

CITIC Securities 3Q Net CNY9.44B Vs. Net CNY6.23B >6030.HK

24 paź 2025, 21:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 paź 2025, 21:24 UTC

Market Talk

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 paź 2025, 21:07 UTC

Earnings

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 paź 2025, 20:58 UTC

Earnings

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 paź 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24 paź 2025, 20:40 UTC

Earnings

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 paź 2025, 20:24 UTC

Earnings

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 paź 2025, 20:23 UTC

Earnings

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 paź 2025, 20:13 UTC

Earnings

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 paź 2025, 20:07 UTC

Market Talk

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 paź 2025, 19:40 UTC

Market Talk

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 paź 2025, 19:35 UTC

Market Talk

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 paź 2025, 19:33 UTC

Earnings

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

111.36% upside

12 Months Forecast

Average 55.63 USD 111.36%

High 74 USD

Low 39 USD

Based on 7 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Zai Lab Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

28.13 / 31.12Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.